Previous 10 | Next 10 |
There's big news for Guardant Health (NASDAQ: GH) shareholders today -- but disappointing news also. This morning, analysts at investment bank Craig-Hallum announced a switch in their bets on cancer-screening biopsy companies, downgrading shares of Exact Sciences (NASDAQ: ...
Summary Guardant Health derives most of its revenue from FDA-approved liquid-biopsy services as opposed to CLIA-waived laboratory-developed tests "LDT". As the FDA prepares to extend its regulatory arm over LDT, it might be a good idea to shift your investment exposure to companie...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will be webcasting a corresponding conference call beginning at 1:30...
Guardant Health (NASDAQ: GH) did relatively well on the market Thursday. The cancer-diagnostics company's shares effectively traded sideways on a day when the S&P 500 index flopped by over 1%. Investors were cautiously optimistic about a new analyst take on the stock. St...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Next-generation assay combines 800+-gene panel with exome-wide methylation detection to provide novel genomic and epigenomic insights into tumor, tumor microenvironment and patient immune responses from a simple blood draw Researchers can access additional modular content to...
Presentations to highlight role of liquid biopsy tests and real-world data to identify biomarkers, predict patient response to therapy, and detect resistance mechanisms in late-stage cancers Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announ...
Oncology diagnostics company Guardant Health (NASDAQ: GH) made its investors happy on Wednesday with an almost 4% rise in its stock price. That performance, far better than the nearly 1% slump of the S&P 500 , was due to the expansion of a collaboration deal with a top name ...
Agreement will leverage GuardantINFORM real-world evidence platform to advance development efforts for core cancer indications Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an expanded collaboration with Merck KGaA, Darmstadt, Germ...
While the broader market is still in the red for the year, it has performed decently in the past three months with the S&P 500 rising by almost 8% in this period. Could this be the start of a new bull market? It's too early to tell. Many companies that have performed even better rec...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...